EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
194
EDITION
4
PRICE
USD 4950
CODE
MCP10421
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
SELECT PLAYERS
AbbVie, Inc.; Amgen, Inc.; Antares Pharma, Inc.; Becton, Dickinson and Company; Consort Medical PLC; Eli Lilly and Company; Haselmeier GmbH; Mylan NV; Owen Mumford Ltd.; SHL Group; Teva Pharmaceutical Industries Ltd.; Ypsomed AG
SEGMENTS
» Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes, Other Therapies)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Rapid Shift from Self-Injectors to Autoinjectors for Easy and Safe Administration of Drugs Drives Demand |
North America: The Largest Market for Autoinjectors |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Rising Prevalence of Targeted Therapies such as Cancer, Rheumatoid Arthritis, Multiple Sclerosis and Diabetes: A Strong Growth Driver |
Table: Number of New Cases of Cancer Worldwide for the Years 2012, 2015, 2020, 2025 and 2030 |
Table: Diabetes Prevalence in the Age-Group of 20-79 Years in Millions by Region for the Years 2018, 2021 and 2025 |
Table: Global Injectable Drug Delivery Market: Revenues in US$ Billion for the Years 2016, 2018, 2020, 2022 and 2024 |
Rising Incidence of Anaphylaxis and Increased Prescription Rate of Epinephrine Autoinjectors Boosts Market Demand |
Increasing Number of Regulatory Approvals for Autoinjectors in Various Diseases |
Generic Autoinjectors Take Center Stage |
Patent Expiry of Biologics to Drive the Demand for Biosimilars |
Strong Government Support and Favorable Reimbursement Policies Propel Market Growth |
Challenges |
Development of Autoinjectors for Multiple Drug Viscosities: A Major Challenge |
Increasing Demand for Alternative Drug Delivery Modes Hampers Market Growth |
Emergence of Oral Diabetic Agents, Oral Insulin and Epinephrine Nasal Sprays Poses Huge Challenge for Autoinjectors Market |
Product Overview |
Autoinjector: Definition |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Autoinjectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Anaphylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Anaphylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Anaphylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
CANADA |
Canada Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
JAPAN |
Japan Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
CHINA |
China Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
EUROPE |
Europe Current & Future Analysis for Autoinjectors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Autoinjectors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
GERMANY |
Germany Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
ITALY |
Italy Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
UNITED KINGDOM |
UK Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
SPAIN |
Spain Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
RUSSIA |
Russia Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Autoinjectors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Autoinjectors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
AUSTRALIA |
Australia Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
INDIA |
India Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
India Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
SOUTH KOREA |
South Korea Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
LATIN AMERICA |
Latin America Current & Future Analysis for Autoinjectors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Autoinjectors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 |
Latin America Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
ARGENTINA |
Argentina Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
BRAZIL |
Brazil Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
MEXICO |
Mexico Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
REST OF LATIN AMERICA |
Rest of Latin America Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
MIDDLE EAST |
Middle East Current & Future Analysis for Autoinjectors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Autoinjectors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Autoinjectors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027 |
Middle East Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
IRAN |
Iran Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
ISRAEL |
Israel Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
SAUDI ARABIA |
Saudi Arabia Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
UNITED ARAB EMIRATES |
UAE Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
REST OF MIDDLE EAST |
Rest of Middle East Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
AFRICA |
Africa Current & Future Analysis for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Autoinjectors by Therapy - Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Autoinjectors by Therapy - Percentage Breakdown of Value Sales for Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes and Other Therapies for the Years 2012, 2020 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 42 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com